30 March 2007
Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infectionAntonio Tursi, Walter Elisei, Giovanni Brandimarte, Gian Marco Giorgetti, Maria Ester Modeo, Fabio Aiello
Med Sci Monit 2007; 13(4): CR187-190 :: ID: 481102
Background: Up to 35% of H. Pylori-positive patients remain infected after a first eradication attempt. Lactoferrin, a natural anti-bacterial glycoprotein, seems a promising tool in treating H. Pylori infection, but it has never been used in second-line treatment. Material/Methods: A prospective, randomized study was conducted on 70 consecutive patients with persistent H. Pylori infection after failure of the first standard treatment schedule. All patients were randomly treated with ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d.), and tinidazole (500 mg b.d.) without (group A) or with (group B) supplementation of bovine lactoferrin (200 mg b.d.). One month after conclusion of therapy, endoscopy was performed in those patients for whom the examination was clinically relevant. The remaining patients were checked by (13)C-urea breath test. Results: Sixty-seven patients were fully compliant and completed the study (33, i.e. 94.28%, in group A and 34, 97.14%, in group B). One group A patient (2.85%) was excluded for protocol violation and one group B patient (2.85%) was lost to follow-up. H. Pylori eradication was obtained in 31/33 (on intention-to-treat: 88.57%, 95%CI: 87-99%) group A patients and in 33/34 (on intention-to-treat: 94.28%, 95%CI: 86-100%) group B patients (p=ns). 16/68 patients (23.53%) experienced side effects (29.41% in group A and 17.64% in group B, p= 0.05). Conclusions: Lactoferrin supplementation was found effective in reducing side-effect incidence. Moreover, it seems capable of achieving a slight (and not statistically significant) improvement in eradicating H. Pylori when used in second-line treatment.
Keywords: Helicobacter Infections - drug therapy, Tinidazole - therapeutic use, Ranitidine - therapeutic use, Prospective Studies, Lactoferrin - therapeutic use, Helicobacter pylori, Anti-Bacterial Agents - therapeutic use, Esomeprazole - therapeutic use, Endoscopy, Gastrointestinal, Breath Tests, Bismuth - therapeutic use, Amoxicillin - therapeutic use
01 December 2022 : EditorialEditorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic
Med Sci Monit 2022; 28:e939088
29 November 2022 : Clinical ResearchRetrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...
Med Sci Monit In Press; DOI: 10.12659/MSM.938647
24 November 2022 : Clinical ResearchA Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vacc...
Med Sci Monit In Press; DOI: 10.12659/MSM.938665
01 December 2022 : EditorialEditorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Funga...
Med Sci Monit 2022; 28:e939088
05 Dec 2022 : Database AnalysisImpact of the De Ritis Ratio on the Prognosis of Patients with Stable Coronary Artery Disease Undergoing Pe...
Med Sci Monit In Press; DOI: 10.12659/MSM.937737
02 Dec 2022 : Clinical ResearchValue of Early Laparoscopic Exploration for Primary Infertile Patients with Patent Fallopian Tubes Complica...
Med Sci Monit In Press; DOI: 10.12659/MSM.938637
30 Nov 2022 : Clinical ResearchRetrospective Evaluation of Hematological and Clinical Factors Associated with 30-Day Mortality in 170 Pati...
Med Sci Monit In Press; DOI: 10.12659/MSM.938674
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996